Author

V. Vukovic

Observed names: V Vukovic, VM Vukovic

Observed institutions: Tufts Medical Center, University of Toronto, Cornell University, Royal Bournemouth Hospital, Churchill Hospital, Institut Jules Bordet, University of Oxford, Aileron (United States), Univerzitetski Klinički Centar Srbije, Instituto Nacional de Enfermedades Neoplásicas, Duke Medical Center, Oxford University Hospitals NHS Trust, Synta Pharmaceuticals (United States), Stiftung Universitätsmedizin Essen

OpenAlex ID: A5110161340

Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan

1997 · V Vukovic, IF Tannock · British Journal of Cancer · 148

Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis.

2000 · V Vukovic, T Nicklee, et al. · PubMed · 26

Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC)

2013 · A Awada, N Spector, et al. · Cancer Research · 4

1654P A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression

2021 · Z. Andric, T. Ceric, et al. · Annals of Oncology · 2

ALRN 6924 induces cell cycle arrest in bone marrow stem cells and hair follicles with dose-dependent degree and duration of effects after a single infusion in healthy volunteers

2022 · S. Henkelman, C. Voors-Pette, et al. · European Journal of Cancer · 1

1791P A phase I pharmacology study of the dual MDMX/MDM2 inhibitor, ALRN 6924, in healthy volunteers

2021 · C. Voors-Pette, W. Aalders, et al. · Annals of Oncology · 1

Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924

2020 · Z. Andric, T. Ceric, et al. · European Journal of Cancer · 1

The Enchanttm Trial: An Open Label Multicenter Phase 2 Window Of Opportunity Study Evaluating Ganetespib (Sta-9090) Monotherapy in Women With Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer (TNBC)

2012 · D. Cameron, M.S. Mano, et al. · Annals of Oncology · 1

Development of acid-labile immunoconjugates for tumor-specific activation of cytotoxins

1995 · C. Mengede, V. Vukovic, et al. · Journal of Cancer Research and Clinical Oncology · 1

Pb1902 the Barcelona‐brno Biomarkers‐only Prognostic Model for Chronic Lymphocytic Leukemia ‐ Single Centre Experience

2019 · K. Tomic, V. Vukovic, et al. · HemaSphere

Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, and Risk of Thromboembolism in Patients With Lymphoma Receiving Chemotherapy

2019 · D. Antic, V. Otasevic, et al. · Hematological Oncology

S1645 Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, and Risk of Thromboembolism in Patients With Lymphoma Receiving Chemotherapy

2019 · V. Otasevic, D. Antic, et al. · HemaSphere

Exploratory Analysis of Circulating Free Dna to Identify Biomarkers Predictive of Outcome in Galaxy-1, a Large Randomized Phase Iib Study of Ganetespib in Combination with Docetaxel Versus Docetaxel Alone in Advanced Nsclc (Nct01348126)

2014 · D. Fennell, J. Shaw, et al. · Annals of Oncology

Works count: 13

Citation count: 185

H-index: 3

I10-index: 2